Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.75 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454968 | 1.00 | AKR1C3 (0.75) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| SCHEMBL3240118 | 0.91 | HIF1A (0.72) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| SCHEMBL14280741 | 0.88 | AKR1C3 (0.84) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL9300 | 0.86 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL29525957 | 0.86 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL29353712 | 0.86 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL3518614 | 0.86 | PTGS2 (1.00) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL23391006 | 0.85 | PTGS2 (0.98) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL1817813 | 0.85 | PTGS2 (0.98) | AKR1C3AKR1C2PTGS2HIF1ALMNA | |
| Indomethacin SCHEMBL6554617 | 0.85 | PTGS2 (0.98) | AKR1C3AKR1C2PTGS2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350093-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORPORATION (US) | 2019-07-16 | — | — | US | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| US-20200188142-A1 | DEGRADABLE IMPLANTABLE MEDICAL DEVICES | ELIXIR MEDICAL CORPORATION (US) | 2020-06-18 | — | — | US | disclosed |
| US-10350093-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORPORATION (US) | 2019-07-16 | — | — | US | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050100594-A1 | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-12 | — | — | US | disclosed |
| US-20050096371-A1 | Topical pharmaceutical compositions | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-05 | — | — | US | disclosed |
| US-20040204413-A1 | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant | OSMOTICA CORP. (VG) | 2004-10-14 | — | — | US | disclosed |
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1362585-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT | Osmotica Corp. (VG) | 2003-11-19 | — | — | EP | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6403630-B1 | ADMINISTERING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR ALONE OR IN COMBINATION WITH HERCEPTIN? ANTIBODY; USED TO TREAT BREAST CANCER | CORNELL RESEARCH FOUNDATION, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | disclosed |
| US-5436265-A | Analgesics or antipyretics | MERCK FROSST CANADA, INC. (CA) | 1995-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225054-A1 | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents | TNF, PTGS1, MIF | AKR1C3 795/4885AKR1C2 746/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.